Navigation Links
ADVENTRX Appoints Vice President of Manufacturing
Date:4/9/2008

SAN DIEGO, April 9, 2008 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (Amex: ANX) announced today that it has appointed Jose Hechavarria to the new position of vice president of manufacturing. Mr. Hechavarria will be responsible for leading the company's planned commercial manufacturing operations.

"We are pleased to have recruited Jose to our team," said Evan M. Levine, ADVENTRX chief executive officer. "He brings experience and leadership in the drug manufacturing and quality arena, and we believe his expertise will be especially valuable as we continue to develop the commercial manufacturing processes for both ANX-530 (vinorelbine emulsion) and ANX-514 (docetaxel emulsion)."

Mr. Hechavarria has over 30 years of experience in the pharmaceutical industry and has overseen all aspects of third-party contract manufacturing. He has held various senior positions at companies including Bristol-Myers Squibb, Dupont Pharmaceuticals, DuPont Merck Pharmaceutical Company as well as the New England Nuclear Corporation. Mr. Hechavarria holds a B.S. in chemical technology from the University of Lowell, an A.S. in nuclear engineering technology from the Wentworth Institute, and has completed post graduate training in parenteral therapeutics agents at the University of Tennessee College of Pharmacy.

About ADVENTRX Pharmaceuticals

ADVENTRX Pharmaceuticals is a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates primarily for the treatment of cancer and infectious disease. The Company seeks to improve the performance and commercial potential of existing treatments by addressing problems associated with these treatment regimens. More information can be found
'/>"/>

SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. ADVENTRX Creates Executive Vice President Position and Announces New Chief Financial Officer
2. ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
3. ADVENTRX Pharmaceuticals to Report Fourth Quarter and Year End 2007 Results
4. Eric K. Rowinsky Joins ADVENTRX Board of Directors
5. ADVENTRX to Present Complete ANX-530 Pharmacokinetic Data at the 2008 American Association for Cancer Research Annual Meeting
6. ADVENTRX Announces Consolidation of Clinical and Management Positions
7. ADVENTRX Pharmaceuticals Reports Third Quarter 2007 Financial Results
8. ADVENTRX Appoints Vice President of Commercialization
9. ADVENTRX Pharmaceuticals to Present at the 2007 BIOInvestor Forum
10. ADVENTRX to Present ANX-514 Preclinical Data at 2007 AACR-NCI-EORTC International Conference
11. ADVENTRX Pharmaceuticals to Present at the 2007 UBS Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)LIBREVILLE, Gabon, December 2 , - "Bolstering Biodiversity in Africa: Everyone,s Problem and Heritage" , Coinciding with the International Year of Biodiversity, 2-3 June 2010 the,Gabonese Rep
(Date:12/2/2009)SINGAPORE, Dec. 2 S*BIO Pte Ltd today announced data presentations on its novel oral JAK2 inhibitor, SB1518, at The American Society of Hematology 51st Annual Meeting and Exposition in New Orleans. ,
(Date:12/2/2009)SHANGHAI, Dec. 2 /PRNewswire-Asia/ -- The world is going through,extraordinary times; markets are in turmoil and uncertainty is part of many,businesses and industries. It turns out that the pharma ind
(Date:12/1/2009)INCLINE VILLAGE, Nev., Dec. 1 PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI ) today announced revenue guidance for the fourth quarter ended December 31, 2009 of approximately $57 million, as compared with
Breaking Biology Technology:Libreville International Conference 2-3 June 2010 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 3S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 4S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 5Pharma and Biotech Leaders to Converge in China at Asia Pharma R&D Leaders 2010 Summit 2Pharma and Biotech Leaders to Converge in China at Asia Pharma R&D Leaders 2010 Summit 3PDL BioPharma Provides Fourth Quarter 2009 Revenue Guidance of Approximately $57 Million 2PDL BioPharma Provides Fourth Quarter 2009 Revenue Guidance of Approximately $57 Million 3
...- Biomedical engineers at The University of Texas ...ave announced pre-clinical test results in the Sep...edicine demonstrating the feasibility of a smart p... in glucose or blood sugar levels and releases ins...tions of the pancreas which produces the blood-sug...
...nc. (Nasdaq:,SQNM) today announced that a live aud...l be provided for its analyst and investor briefin...the event are as follows: (Logo: http://www.new... Sequenom Today and Tomorrow, When: Monday...here: http://www.sequenom.com , How: Liv...
...l Alliance, the leading,management consulting firm...dustries, today announced that Ben Bonifant, Vice ...ent practice, will moderate a panel discussion,at ...rence hosted by,Windhover Information. The confere...iott Financial Center in New York City. The panel...
Other Biology Technology:Smart insulin nanostructures pass feasibility test, UT study reports 2Sequenom to Webcast Analyst and Investor Briefing Presentation on September 24 2Campbell Alliance to Moderate Senior-Level Panel Discussion at Windhover Pharmaceutical Strategic Alliances Conference 2Campbell Alliance to Moderate Senior-Level Panel Discussion at Windhover Pharmaceutical Strategic Alliances Conference 3
(Date:12/4/2009)The electroencephalogram (EEG) is widely used by physicians and scientists to study brain function and to diagnose neurological disorders. However, it has remained largely unknown whether the electrod
(Date:12/4/2009)Using a new mathematical model of heart cells, University of Iowa investigators have shown how activation of a critical enzyme, calmodulin kinase II (CaM kinase), disrupts the electrical activity of h
(Date:12/3/2009)WALL, N.J., Dec. 3 BIO-key International, Inc. (OTC Bulletin Board: BKYI), a leader in wireless public safety and finger-based biometric identification solutions, announced that a majority of its sha
Breaking Biology News(10 mins):How to read brain activity? 2U-Iowa study helps advance heart-related research 2BIO-key(R) Shareholders Overwhelmingly Approve Sale of Law Enforcement Division 2BIO-key(R) Shareholders Overwhelmingly Approve Sale of Law Enforcement Division 3Biopolymers Symposium 2009 Teams with Carbonfund org to Create a Zero Carbon Event 13295 1Biopolymers Symposium 2009 Teams with Carbonfund org to Create a Zero Carbon Event 13295 210 Steps to Affordable Health Care Overhaul 3A NCPA Proposes Reforms to Protect Choices Control Costs and Preserve Access 53252 110 Steps to Affordable Health Care Overhaul 3A NCPA Proposes Reforms to Protect Choices Control Costs and Preserve Access 53252 2Human Pheromones 3A Whats Purported Whats Supported A White Paper Published by The Sense of Smell Institute 53249 1
... for Medical Research (Burnham) have discovered a ... Sporadic Inclusion Body Myositis (sIBM). sIBM is ...men, causing muscles to gradually weaken and waste...known, but it is the most common muscle disease am...iliarity, it is probably underdiagnosed. This disc...
...cal Research Institute report that bats significan...In a lowland tropical rainforest in Panama, bats c...cts as do birds. This landmark study in the journa...ats and birds to protect plants via insect predati...dy by the authors suggested that bats were underes...
... University have pinpointed a small group of genes...w to produce a hormone that is key to their develo...ich hormone production in plants affects both a pl...nvironments. , Dr. Jose Alonso, assistant profes...nt biologists from NC State, Germany and the Czech...
Other Biology News:RING finger protein 5 may guide treatment for muscle disease in older adults 2RING finger protein 5 may guide treatment for muscle disease in older adults 3Smithsonian researchers show major role of bats in plant protection 2NC State researchers identify genes key to hormone production in plants 2
Rabbit Anti-QKI Polyclonal Antibody, Unconjugated from Bethyl Laboratories
Acridinium Ester Trigger Solutions from Assay Designs/Stressgen Bioreagents
Mouse Anti-St. Louis encephalitis Monoclonal Antibody, Unconjugated, Clone 6B5A-2 from ABR-Affinity BioReagents
...bbit polyclonal to Kv4.2 Immunogen Synthetic pep...rresponding to amino acids 23-43 of Rat Kv4.2. Re...cted to cross-react with Human (100% identity with... Rabbit (100% identity with immunogen) and Ferret ...
Biology Products: